Greensboro, NC — Novartis Animal Health US, Inc. has created a new website focused exclusively on scours prevention in beef and dairy calves. The website, www.scourbos.com, features Scour Bos®, a broad-spectrum vaccine that protects against the most common bacterial and viral pathogens that cause calf scours.
“Scours continues to be the leading cause of mortality and sickness among calves,” said Doug Scholz, director of veterinary services at Novartis Animal Health. “Death loss, treatment costs and poor performance resulting from scours can add up to thousands of dollars in economic losses for a single herd every year. Our goal with this website is to provide producers with prevention tips and management strategies that can significantly reduce the risk of scours on their farms.”
The website includes disease information, expert tips and vaccination guidelines. Visitors to www.scourbos.com can also learn how veterinarians and producers in different geographic regions of the U.S. with unique herd health challenges are using Scour Bos as part of a comprehensive scours management plan.
Containing nine antigens, Scour Bos is the only scours vaccine that provides protection against four E. coli isolates, three rotaviruses, coronavirus and Clostridium perfringens Type C in a single dose.
“Preventing calf scours requires careful management of the dam, the environment and the calf,” said Scholz. “The first step in a scours management program is immunization of the dam with an effective vaccine like Scour Bos, delivering passive immunity via high levels of maternal antibodies passed to the calf through colostrum.”
Scour Bos can be given to beef cows up to 16 weeks precalving and at dry off for dairy herds, which helps ensure maternal antibodies circulating in the dam are as high as possible before they are transferred to the colostrum. The 16 week window of administration also provides maximum convenience and flexibility for producers.
To learn more about Scour Bos and cattle health management tips that prevent scours outbreaks, visit www.scourbos.com or contact your Novartis Animal Health representative.
The foregoing release contains forward-looking statements that can be identified by terminology such as "can," "goal," or similar expressions, or by express or implied discussions regarding potential future revenues from Scour Bos. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Scour Bos will achieve any particular levels of revenue in the future. In particular, management's expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Headquartered in Greensboro, NC, Novartis Animal Health US, Inc. researches, develops and commercializes leading animal treatments that meet the needs of pet owners, farmers and veterinarians. Part of the Basel, Switzerland-based Novartis Animal Health global organization, the US business is the largest of the 40 countries where Novartis Animal Health operates. For more information about Novartis Animal Health US, Inc., please consult http://www.ah.novartis.us.
Novartis Animal Health US, Inc. is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group’s continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.